Director Michael Purcell buys 1.25M Hepion (HEPA) shares

Rhea-AI Filing Summary

Hepion Pharmaceuticals director Michael J. Purcell bought 1,250,000 shares of common stock in an open-market purchase. He paid $0.04 per share, for a total of about $50,000. Following this transaction, he directly owns 1,250,000 Hepion Pharmaceuticals common shares.

Insider Trade Summary

Net Buyer: 1,250,000 shares ($50,000)

Net Buy 1 txn

Insider Purcell Michael J.

Role null

Bought 1,250,000 shs ($50K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $0.0001 per share	1,250,000	$0.04	$50K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 1,250,000 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 1,250,000 shares Purchase price per share: $0.04 per share Approximate transaction value: $50,000 +1 more

4 metrics

Shares purchased 1,250,000 shares Open-market purchase of common stock

Purchase price per share $0.04 per share Open-market transaction price

Approximate transaction value $50,000 1,250,000 shares × $0.04 purchase price

Shares owned after transaction 1,250,000 shares Direct holdings following reported purchase

Key Terms

open-market purchase, Common Stock, par value $0.0001 per share, direct ownership

3 terms

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock, par value $0.0001 per share financial

"security_title": "Common Stock, par value $0.0001 per share""

direct ownership financial

"ownership_type": "direct""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Purcell Michael J.

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	04/21/2026		P		1,250,000	A	$0.04	1,250,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Michael Purcell	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Hepion Pharmaceuticals (HEPA) disclose for Michael J. Purcell?

Director Michael J. Purcell bought 1,250,000 Hepion Pharmaceuticals common shares in an open-market transaction. He paid $0.04 per share, making the total purchase approximately $50,000, and now directly owns 1,250,000 shares after the transaction.

Was the Hepion Pharmaceuticals (HEPA) Form 4 transaction an insider buy or sell?

The Form 4 reports an insider buy. Director Michael J. Purcell executed an open-market purchase of 1,250,000 Hepion Pharmaceuticals common shares at $0.04 per share, increasing his direct holdings to 1,250,000 shares following the transaction.

How many Hepion Pharmaceuticals (HEPA) shares does Michael J. Purcell hold after the reported trade?

After the reported trade, Michael J. Purcell directly holds 1,250,000 Hepion Pharmaceuticals common shares. This entire position reflects the 1,250,000 shares he purchased in the open market at $0.04 per share in the disclosed transaction.

What was the approximate dollar value of Michael J. Purcell’s Hepion Pharmaceuticals (HEPA) share purchase?

The approximate dollar value of the purchase is $50,000. Michael J. Purcell acquired 1,250,000 Hepion Pharmaceuticals common shares at $0.04 per share in an open-market transaction, as detailed in the Form 4 insider trading report.

What type of security did Michael J. Purcell buy in Hepion Pharmaceuticals (HEPA)?

He bought Hepion Pharmaceuticals common stock with a par value of $0.0001 per share. The transaction involved 1,250,000 common shares purchased in the open market at a price of $0.04 per share, increasing his direct ownership stake.